Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

John Glaspy, M.D., M.P.H.
John Glaspy, M.D., M.P.H.


Internal Medicine
Medical Oncology

General Information:



Professor, Department of Medicine, Hematology/Oncology
Physician, Department of Medicine, Hematology/Oncology
Estelle, Abe and Marjorie Sanders Endowed Chair in Cancer Research, JCCC
Co-Chair, Protocol Review and Monitoring System (PRMS)
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

UCLA Medical Center, Santa Monica
Ronald Reagan UCLA Medical Center


Hematology and Oncology, UCLA School of Medicine, 1982 - 1983
Internal Medicine, UCLA School of Medicine, 1980 - 1982
Internal Medicine, UCLA School of Medicine, 1979 - 1980
Medical Degree:
M.D., UCLA School of Medicine, 1979
M.P.H., UCLA Fielding School of Public Health, 1979


Board Certification(s):
Hematology, American Board of Internal Medicine, 1986
Medical Oncology, American Board of Internal Medicine, 1985
Internal Medicine, American Board of Internal Medicine, 1982

Contact Information:

(310) 794-4955 Appointments
(310) 267-5964 Administrative
(310) 794-4955 Office

Practice Information:

Clinical Interest(s):
Breast Cancer
General Hematology
General Oncology
Stem Cell Transplant Breast

Scientific Interest(s):

Dr. John Glaspy's research focuses on the use of bone marrow transplants and chemotherapy for breast cancer and melanomas. He is exploring the use of low-fat diet-based treatments as an alternative to unsuccessful chemotherapy and/or bone marrow transplants.

Selected Cancer-Related Publications:

Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A, Huang RR. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011 Jun 15;17(12):4101-9. Epub 2011 May 10

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83.

Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011 Dec 14;6(12):e28973.

Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, Mischel PS, Comin-Anduix B, Ribas A. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 2011 May 24;9:76.

Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res. 2009 Jan 1;15(1):390-9.